Inclisiran

ORION-1
ORION-1 Trial A placebo-controlled, double-blind, randomized trial to compare the effect of different doses of ALN-PCSSC given as single or multiple subcutaneous injections in subjects with high cardiovascular risk and elevated LDL-C Aim Primary: To evaluate the effect of ALN-PCSSC treatment on LDL-C levels at…
read more »Posted on 11 July 2016 |
Posted in Inclisiran


Prof Kausik Ray: Inclisiran, new kid on the block, looks good in ORION
Watch out PCSK9 monoclonal antibodies: inclisiran (formerly known as PCSK9si and ALN-PCSsc) has made its mark at ACC.2017. Results of the phase 2 ORION-1 trial in patients with elevated LDL cholesterol despite maximally tolerated statin therapy, showed that 2 single injections of inclisiran 300 mg…
read more »Posted on 18 March 2017 |
Posted by Kausik Ray | Posted in Videos,
66th Annual Scientific Sessions of the American College of Cardiology 2017